Chapter 64 Antithrombotic agents for stroke prevention

Handbook of Clinical Neurology

Volumn 94, Issue , 2008, Pages 1277-1294

  Schwartz, Neil E ^a   Diener, Hans christoph ^b   Albers, Gregory W ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66149084812     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(08)94064-1     Document Type: Review

References (141)

1. Agah R., Plow E.F., and Topol E.J. GPIIb-IIIa antagonists. In: Michelson A.D. (Ed). Platelets (2002), Academic Press, Amsterdam 769-785
2. Albers G.W. Choice of endpoints in antiplatelet trials: which outcomes are most relevant to stroke patients?. Neurology 54 (2000) 1022-1028
3. Albers G.W. Can the ESPRIT results end the antiplatelet battle between neurologists and cardiologists?. Nat Clin Pract Cardiovasc Med 4 (2007) 118-119
4. Albers G.W., Hart R.G., Lutsep H.L., et al. AHA scientific statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 30 (1999) 2502-2511
5. Albers G.W., Amarenco P., Easton J.D., et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 483S-512S
6. Algra A., and van Gijn J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 60 (1996) 197-199
7. American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia. Part II: endpoint results. Stroke 16 (1985) 406-415
8. Ansell J., Hirsh J., Poller L., et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204S-233S
9. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
10. Awtry E.H., and Loscalzo J. Aspirin. In: Michelson A.D. (Ed). Platelets (2002), Academic Press, Amsterdam 745-768
11. Barnett H.J., Eliasziw M., and Meldrum H.E. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 332 (1995) 238-248
12. Beaumont J.L., Caen J., and Bernard J. Influence de l'acide acetyl salicylique dans les maladies hémorrhagiques. Sang 27 (1956) 243-248
13. Bennett C.L., Weinberg P.D., Rozenberg-Ben-Dror K., et al. Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med 128 (1998) 541-544
14. Bhatt D.L., Foody J., Hirsch A.T., et al. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherothrombosis. J Am Coll Cardiol 35 (2000) 326
15. Bhatt D.L., Chew D.P., Hirsch A.T., et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 103 (2001) 363-368
16. Bhatt D.L., Marso S.P., Hirsch A.T., et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90 (2002) 625-628
17. Bhatt D.L., Fox K.A., Hacke W., et al., CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
18. Blatrix C. Allongement du temps de saignement sons l'influence de certain médicaments. Nouv Rev Fr Hematol 3 (1963) 346-351
19. Bousser M.G., Eschwege E., Haguenau M., et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14 (1983) 5-14
20. Broderick J.P., Phillips S.J., O'Fallon W.M., et al. Relationship of cardiac disease to stroke occurrence, recurrence, and mortality. Stroke 23 (1992) 1250-1256
21. Bronnum-Hansen H., Davidsen M., Thorvaldsen P., and Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke 32 (2001) 2131-2136
22. Burch J.W., and Majerus P.W. The role of prostaglandins in platelet function. Semin Hematol 16 (1979) 196-207
23. Cappelleri J.C., Lau J., Kupelnick B., et al. Efficacy and safety of different aspirin dosages on vascular diseases in high-risk patients. A metaregression analysis. Online J Curr Clin Trials (1995) Doc No. 174
24. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
25. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349 (1997) 1641-1649
26. Catella-Lawson F., Reilly M.P., Kapoor S.C., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
27. Chaturvedi S., Bruno A., Feasby T., et al. Carotid endarterectomy-an evidence-based review. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 65 (2005) 794-801
28. Chen D.K., Kim J.S., and Sutton D.M. Thrombotic thrombocytopenic purpura associated with ticlopidine use: a report of 3 cases and review of the literature. Arch Intern Med 159 (1999) 311-314
29. Chen Z.M., Sandercock P., Pan H.C., et al. Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 31 (2000) 1240-1249
30. Chew D.P., Bhatt D.L., Sapp S., et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103 (2001) 201-206
31. Chimowitz M.I., Lynn M.J., Howlett-Smith H., et al., Warfarin-Aspirin Symptomatic Intracranial Disease Trial Investigators. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 352 (2005) 1305-1316
32. Coller B.S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 92 (1995) 2373-2380
33. Craven L.L. Prevention of coronary thrombosis and cerebral thrombosis. Miss Valley Med J 78 (1956) 213-215
34. Curtin R., Cox D., and Fitzgerald D. Clopidogrel and ticlopidine. In: Michelson A.D. (Ed). Platelets (2002), Academic Press, Amsterdam 787-801
35. Diener H.C. Modified-release dipyridamole combined with aspirin for secondary stroke prevention. J Aging Health 1 (2005) 19-26
36. Diener H.C., Cunha L., Forbes C., et al. European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 (1996) 1-13
37. Diener H.C., Darius H., Bertrand-Hardy J.M., et al., European Stroke Prevention Study 2. Cardiac safety in European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 55 (2001) 162-163
38. Diener H.C., Bogousslavsky J., Brass L.M., et al., MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364 (2004) 331-337
39. Diener H.C., Ringleb P.A., and Savi P. Clopidogrel for secondary prevention of stroke. Expert Opin Pharmacother 6 (2005) 755-764
40. Dreser H. Pharmacologisches über Aspirin (Acetylsalicyl-saüre). Pflugers Arch 76 (1899) 306-318
41. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325 (1991) 1261-1266
42. Easton J.D. Evidence with antiplatelet therapy and ADP-receptor antagonists. Cerebrovasc Dis 16 (2003) 20-26
43. Eikelboom J.W., and Hankey G.J. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol 41 (2003) 966-968
44. Eikelboom J.W., Hirsh J., Weitz J.I., et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
45. Eisert W.G. How to get from antiplatelet to antithrombotic treatment. Am J Ther 8 (2001) 443-449
46. Eisert W.G. Near-field amplification of antithrombotic effects of dipyridamole through vessel wall cells. Neurology 57 (2001) S20-S23
47. ESPRIT Study Group, Halkes P.H., van Gijn J., Kappelle L.J., et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367 (2006) 1665-1673
48. ESPS Group. The European Stroke Prevention Study (ESPS). Principal end-points. Lancet 2 (1987) 1351-1354
49. European Atrial Fibrillation Trial (EAFT) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 (1993) 1255-1262
50. European Carotid Surgery Trialists' Collaborative Group. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 351 (1998) 1379-1387
51. European Stroke Initiative Executive Committee and the EUSI Writing Committee. European stroke initiative recommendations for stroke management-update 2003. Cerebrovasc Dis 16 (2003) 311-337
52. Evans G., Mustard J.F., and Packham M.A. Thromboembolism. In: Fields W.S., and Hass W.K. (Eds). Aspirin, Platelets and Stroke Background for a Clinical Trial (1971), Warren H Green, Inc., St. Louis, MO 59-73
53. Farrell B., Godwin J., Richards S., et al. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
54. FitzGerald G.A. Dipyridamole. N Engl J Med 316 (1987) 1247-1257
55. Gent M., Blakely J.A., Easton J.D., et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1 (1989) 1215-1220
56. Gorelick P.B., and Weisman S.M. Risk of hemorrhagic stroke with aspirin use: an update. Stroke 36 (2005) 1801-1807
57. Gorelick P.B., Richardson D., Kelly M., et al., African American Antiplatelet Stroke Prevention Study Investigators. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 289 (2003) 2947-2957
58. Gotoh F., Tohgi H., Hirai S., et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral ischemia. J Stroke Cerebrovasc Dis 9 (2000) 147-157
59. Gross M., and Greenberg L.A. The Salicylates: A Critical Bibliographic Review (1948), Hillhouse Press, Conn
60. Gross P.L., and Aird W.C. The endothelium and thrombosis. Semin Thromb Hemost 26 (2000) 463-478
61. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin nonresponder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
62. Guiraud-Chaumeil B., Rascol A., David J., et al. Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial. Rev Neurol (Paris) 138 (1982) 367-385
63. Gurbel P.A., Bliden K.P., Hiatt B.L., et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
64. Hankey G.J., and Eikelboom J.W. Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks. Neurology 64 (2005) 1117-1121
65. Hankey G.J., Sudlow C.L., and Dunbabin D.W. Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials. Stroke 31 (2000) 1779-1784
66. Hanson J., de Leval X., David J.L., et al. Progress in the field of GPIIb/IIIa antagonists. Curr Med Chem Cardiovasc Hematol Agents 2 (2004) 157-167
67. Hartmann A., Rundek T., Mast H., et al. Mortality and causes of death after first ischemic stroke: the Northern Manhattan Stroke Study. Neurology 57 (2001) 2000-2005
68. Hass W.K., Easton J.D., Adams Jr. H.P., et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321 (1989) 501-507
69. Helgason C.M., Bolin K.M., Hoff J.A., et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
70. Hollopeter G., Jantzen H.M., Vincent D., et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409 (2001) 202-207
71. Homma S., Sacco R.L., Di Tullio M.R., et al., PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 105 (2002) 2625-2631
72. Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost 82 (1999) 435-438
73. Ikeda Y., Sudo T., and Kimura Y. Cilostazol. In: Michelson A.D. (Ed). Platelets (2002), Academic Press, Amsterdam 817-823
74. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 349 (1997) 1569-1581
75. Johnson E.S., Lanes S.F., Wentworth III C.E., et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 159 (1999) 1248-1253
76. Johnston S.C., Gress D.E., Browner W.S., et al. Short-term prognosis after emergency department diagnosis of TIA. JAMA 284 (2000) 2901-2906
77. Kernan W., Viscoli C., Brass L., et al. The stroke prognosis instrument II (SPI-II): a clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. Stroke 31 (2000) 456-462
78. Kwon S.U., Cho Y.J., Koo J.S., et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36 (2005) 782-786
79. Leonardi-Bee J., Bath P.M., Bousser M.G., et al., Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 36 (2005) 162-168
80. Levine S.R., Brey R.L., Tilley B.C., et al., APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA 291 (2004) 576-584
81. Lindgren A., Husted S., Staaf G., et al. Dipyridamole and headache-a pilot study of initial dose titration. J Neurol Sci 223 (2004) 179-184
82. Loll P.J., Picot D., and Garavito R.M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 2 (1995) 637-643
83. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
84. Majerus P.W. Arachidonate metabolism in vascular disorders. J Clin Invest 72 (1983) 1521-1525
85. Markus H.S., Droste D.W., Kaps M., et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 111 (2005) 2233-2240
86. Matetzky S., Shenkman B., Guetta V., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
87. Matias-Guiu J., Ferro J.M., Alvarez-Sabin J., et al., TACIP Investigators. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 34 (2003) 840-848
88. Messmore Jr. H.L., Jeske W.P., Wehrmacher W., et al. Antiplatelet agents: current drugs and future trends. Hematol Oncol Clin North Am 19 (2005) 87-117
89. Mohr J.P., Thompson J.L., Lazar R.M., et al., Warfarin-Aspirin Recurrent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 345 (2001) 1444-1451
90. Mueller R.L., and Scheidt S. History of drugs for thrombotic disease. Discovery, development, and directions for the future. Circulation 89 (1994) 432-449
91. Muller I., Besta F., Schulz C., et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
92. Murata T., Ushikubi F., Matsuoka T., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388 (1997) 678-682
93. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325 (1991) 445-453
94. Oishi M., Mochizuki Y., Shikata E., et al. Effect of cilostazol on cerebral blood flows in chronic stage of cerebral circulation. Keio J Med 49 (2000) A145-A147
95. O'Neill W.W., Serruys P., Knudtson M., et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. Evaluation of oral xemilofiban in controlling thrombotic events. N Engl J Med 342 (2000) 1316-1324
96. Patrono C., Bachmann F., Baigent C., et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J 25 (2004) 166-181
97. Plow E.F., Pierschbacher M.D., Ruoslahti E., et al. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets. Proc Natl Acad Sci USA 82 (1985) 8057-8061
98. Quick A.J. Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 252 (1966) 265-269
99. Quinn M.J., and Topol E.J. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2 (2001) 341-352
100. Rao A.K. Inherited defects in platelet signaling mechanisms. J Thromb Haemost 1 (2003) 671-681
101. Ringleb P.A., Bhatt D.L., Hirsch A.T., et al., Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 35 (2004) 528-532
102. Roderick P.J., Wilkes H.C., and Meade T.W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. J Clin Pharmacol 35 (1993) 219-226
103. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
104. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56 (1975) 624-632
105. Rothwell P.M., Warlow C.P., and on behalf of the European Carotid Surgery Trialists Collaborative Group. Prediction of benefit from carotid endarterectomy in individual patients: a risk-modelling study. Lancet 353 (1999) 2105-2110
106. Rothwell P.M., Eliasziv M., Gutnikov S.A., et al., Carotid Endaterectomy Trialists' Collaboration. Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 361 (2003) 107-116
107. Rothwell P.M., Giles M.F., Flossmann E., et al. A simple score (ABCD) to identify individuals at high early risk of stroke after transient ischaemic attack. Lancet 388 (2005) 29-36
108. Ruggeri Z.M. Platelets in atherothrombosis. Nat Med 8 (2002) 1227-1234
109. Sacco R.L. Risk factors and outcomes for ischemic stroke. Neurology 45 (1995) S10-S14
110. Sacco R.L., Sivenius J., and Diener H.C. Efficacy of aspirin plus extended-release dipyridamole in preventing recurrent stroke in high-risk populations. Arch Neurol 62 (2005) 403-408
111. Sacco R.L., Adams R., Albers G., et al., American Heart Association/American Stroke Association Council on Stroke, Council on Cardiovascular Radiology and Intervention American Academy of Neurology. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation 113 (2006) e409-e449
112. Salem D.N., Stein P.D., Al-Ahmed A., et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 457S-482S
113. Savi P., Laplace M.C., Maffrand J.P., et al. Binding of [3H]-2-methylthio ADP to rat platelets-effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 269 (1994) 772-777
114. Savi P., Pereillo J.M., Uzabiaga M.F., et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost 84 (2000) 891-896
115. Schafer A.I. Antiplatelet therapy. Am J Med 101 (1996) 199-209
116. Schafer A.I., and Kroll M.H. Nonatheromatous arterial thrombosis. Annu Rev Med 44 (1993) 155-170
117. Schror K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 123 (1997) 349-356
118. Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation 103 (2001) 1727-1733
119. Serebruany V.L., Steinhubl S.R., Berger P.B., et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 95 (2005) 1218-1222
120. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 429S-456S
121. Smith W.L., Garavito R.M., and DeWitt D.L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 271 (1996) 33157-33160
122. Steinhubl S.R., Berger P.B., Mann III J.T., et al., CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
123. Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 42 (1997) 857-865
124. Sudlow C., and Baigent C. Antiplatelet treatment (Secondary Prevention of Stroke and Secondary Prevention of Ischaemic Cardiac Events). In: Godlee F., and Goldman D. (Eds). Clinical Evidence (Issue 3) (2000), BMJ Publishing Group and the American College of Physicians, American Society of Internal Medicine, London
125. Sudo T., Tachibana K., Toga K., et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 59 (2000) 347-356
126. Swedish Aspirin Low-Dose Trial Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338 (1991) 1345-1349
127. SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. Lancet 355 (2000) 337-345
128. Sztriha L.K., Sas K., and Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci 229/230 (2005) 163-169
129. Tanaka T., Ishikawa T., Hagiwara M., et al. Effects of cilostazol, a selective camp phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 36 (1988) 313-320
130. Taylor D.W., Barnett H.J., Haynes R.B., et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. Lancet 353 (1999) 2179-2184
131. Topol E.J., Easton D., Harrington R.A., et al., Blockade of the Glycoprotein, IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108 (2003) 399-406
132. Van Giezen J.J., and Humphries R.G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin Thromb Hemost 31 (2005) 195-204
133. Ware J.A., and Heistad D.D. Seminars in medicine of the Beth Israel Hospital, Boston. Platelet-endothelium interactions. N Engl J Med 328 (1993) 628-635
134. Weimar C., Roth M.P., Zillessen G., et al., German Stroke Data Base Collaborators. Complications following acute ischemic stroke. Eur Neurol 48 (2002) 133-140
135. Weir N.U., Demchuk A.M., Buchan A.M., et al. Stroke prevention. Matching therapy to the patient with TIA. Postgrad Med 117 (2005) 26-30
136. Wilterdink J.L., and Easton J.D. Dipyridamole plus aspirin in cerebrovascular disease. Arch Neurol 56 (1999) 1087-1092
137. Wolf P.A., D'Agostino B., Belanger A.J., et al. Probability of stroke: a risk profile from the Framingham study. Stroke 22 (1991) 312-318
138. World Health Organization. The World Health Report: Reducing Risks, Promoting Healthy Life (2002), WHO, Geneva, Switzerland
139. Yadav J.S., Wholey M.H., Kuntz R.E., et al., Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy Investigators. Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351 (2004) 1493-1501
140. Yusuf S., Zhao F., Mehta S.R., et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
141. Ziegler S., Schillinger M., Funk M., et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 36 (2005) 1394-1399